Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 23 Publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MYXGeY5kfGmxbjDBd5NigQ>? NEXncnAxNjFvM{Cg{txO MlGyOFghcA>? MYPpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> M2jYeFI3PTF|MUey
H460 MXjGeY5kfGmxbjDBd5NigQ>? NYTEVlZROC5zLUOwJO69VQ>? MXG0PEBp NYfmSpE4cW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? NHrMbVMzPjVzM{G3Ni=>
HKESC-2 NUixZW9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnLNlDDqM7:TR?= NHXKS2Q1QMLiaNMg MmLhd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh MlLNNlY1PzR4OUO=
CaES-17 M2LGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj0boQzOMLizszN Mn33OFjDqGkEoB?= NXrpPIVWe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi NGXHXG4zPjR5NE[5Ny=>
HKESC-2 NYnwcoptSXCxcITvd4l{KEG|c3H5 NYLiXVZZOjEEoN88US=> M1TZRVQ5yqCqwrC= MXjy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz Mk\GNlY1PzR4OUO=
CaES-17 NX7nWZZtSXCxcITvd4l{KEG|c3H5 M3fRWlIxyqEQvF2= M3nn[lQ5yqCqwrC= NW\h[WxDemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? NIfnUIwzPjR5NE[5Ny=>
A549 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[yO5E2NTF4MDFOwG0> M{ftUVQ5yqCqwrC= NXW1[VY4TE2VTx?= NFzFR41KSzVyPUG2N{41KM7:TR?= NVnqNGdIOjZ2NkS2OFM>
HCC827 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm1VGNnPS1zNkCg{txO MUO0POKhcMLi M33OTGROW09? Ml7JTWM2OD14OT6yJO69VQ>? M2TheVI3PDZ2NkSz
A549 NXiwb5VbSXCxcITvd4l{KEG|c3H5 M3rwbFgxKML3TR?= Mle3OFjDqGkEoB?= M1nH[WROW09? NWPERY5ucW6mdXPld{BieG:ydH;zbZM> M3r6RVI3PDZ2NkSz
HCC827 M1HlWGFxd3C2b4Ppd{BCe3OjeR?= MVy4NEDDvU1? M4LoOVQ5yqCqwrC= M1vrfWROW09? NIDNbnlqdmS3Y3XzJIFxd3C2b4Ppdy=> M1XC[VI3PDZ2NkSz
SGC-7901/DDP NIjNNYdHfW6ldHnvckBCe3OjeR?= NVPGR2pjOTEEoNM1US=> Ml20NlQhcA>? M{\ib4lvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MUSyOlQxPzZ3Mx?=
SGC-7901  Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHrPXQzPMLiaNMg MUXJR|UxRTFzNT6wPEDPxE1? M3SxV|I3PDB5NkWz
SGC-7901/DDP MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfpVZpLOjUEoHlCpC=> NETSOWFKSzVyPUO1MlQ2KM7:TR?= NITJPZYzPjRyN{[1Ny=>
SGC-7901/DDP NHflcIxCeG:ydH;zbZMhSXO|YYm= NYLHSGJvOTEEoNM1US=> NWjsUldIOjRiaB?= MnjzbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> MoSyNlY1ODd4NUO=
SGC-7901/DDP M1nhR2Z2dmO2aX;uJGF{e2G7 NFrmOVAyOMLiwsXN NW\KNpFvOjRiaB?= NUnoeZdmcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= M3PKRlI3PDB5NkWz
SGC-7901/DDP M{\kSWZ2dmO2aX;uJGF{e2G7 NX\NV|ZEOTEEoNM1US=> M17pdVI1KGh? MnHUZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu NXPsWoxkOjZ2MEe2OVM>
H357 NFjyVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvEN|VNPy53L{GwJO69VQ>? MlXWOFghcA>? NWrPfGVoTE2VTx?= NE\mdI1qdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5 MXiyOlAxQTh5NB?=
TAF NFjFToxHfW6ldHnvckBCe3OjeR?= MnXpNVDDqML3TR?= MoXUO{Bl NUD2ZpRG[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= NX3Ze|hQOjV7OEexNlc>
TAF MWfGeY5kfGmxbjDBd5NigQ>? NFfqN3cyOMLiwsXN M{XGPFMxNTF{MDDtbY4> MnfadI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n Mn71NlU6QDdzMke=
TAF NI[1RldHfW6ldHnvckBCe3OjeR?= NVjE[YM4OTEEoNM1US=> NVfOZWViPDhiaB?= M4TmNIlv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MXSyOVk5PzF{Nx?=
PANC-1 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;mb|czOC94MD:xNFAh|ryP MVOyOE81QC95MjDo NV[2Tox3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NEW2cGMzPTl5M{C2Ni=>
PANC-1 MV\GeY5kfGmxbjDBd5NigQ>? MVeyNE83OC9zMECg{txO MY[yOEBp MknvZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MXSyOVk4OzB4Mh?=
HeLa  NEXvW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPWnR5OjEEoN88UeKh NHz0SmIzPMLiaB?= NUTCdHZL\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NFfZV3ozPTd5MESyNy=>
SACC-83 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfvUG5wOjEEoN88UeKh MV2yOOKhcA>? MVPlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MknHNlU4PzB2MkO=
HeLa  M13WN2Fxd3C2b4Ppd{BCe3OjeR?= M4DlflIxyqEQvF5CpC=> MVWyOOKhcA>? NI[0[I1mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ MVqyOVc4ODR{Mx?=
SACC-83 MX\BdI9xfG:|aYOgRZN{[Xl? NIj0flczOMLizszNxsA> MYiyOOKhcA>? NUDFbmFs\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? NGX4[JQzPTd5MESyNy=>
HeLa  NWfISXFuTnWwY4Tpc44hSXO|YYm= M4OwTFIxNzRyL{iwJO69VQ>? Moe0NlTDqGh? NH3LZZV2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? MVqyOVc4ODR{Mx?=
SACC-83 Mn7VSpVv[3Srb36gRZN{[Xl? NYrXN3hHOjBxNECvPFAh|ryP NXzlNWd1OjUEoHi= NIPtVFJ2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? NUmxTlRDOjV5N{C0NlM>
HLCZ01 NGfsU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuxd5dSOOLCk{[wxsDDvU1? MYi0PEBp NIe4dGJFVVOR NX[xWppDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUDqbmY6OjV5MkS4PVk>
HLCZ01 MXPGeY5kfGmxbjDBd5NigQ>? MluwOFDDqM7:TR?= MYCyOEBp MVrEUXNQ M1u4Uolv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MX:yOVczPDh7OR?=
HLCZ01 NYnJ[I9kSXCxcITvd4l{KEG|c3H5 MnG2OFDDqM7:TR?= MUOyOEBp MYnEUXNQ M2\VXYVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? M2PMcFI2PzJ2OEm5
HLCZ01 NV:2T3R{TnWwY4Tpc44hSXO|YYm= MnLiOFDDqM7:TR?= MWWyOEBp MoT1SG1UVw>? NXnPUZZUcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y MX2yOVczPDh7OR?=
MGC803 NH;XWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\WNE03OCEQvF2= NFXnVlI4OiCq MljUTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= MkD3NlU4ODF|N{i=
SGC7901 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ESFAuPjBizszN NX3jbFBnPzJiaB?= MYHJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= NWPrZ|A{OjV5MEGzO|g>
MGC803 M{S1V2Z2dmO2aX;uJGF{e2G7 M3fNZlQxyqEQvF2= M3LmN|gwOTZxMkSgbC=> NXT0bm1nfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v MV[yOVcxOTN5OB?=
SGC7901 M{Xj[mZ2dmO2aX;uJGF{e2G7 NHmwW2s1OMLizszN NV;KNGRlQC9zNj:yOEBp M4\NfZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NF6xWFAzPTdyMUO3PC=>
MCF-7  MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXHbYgyNzFyIN88US=> Ml\rO|IhcA>? MoThSG1UVw>? MmPR[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? M4XmcFI2PjZ5NUGw
MDA-MB-231  M1jUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3oPVgyNzFyIN88US=> M3;DdFczKGh? M{[3T2ROW09? NEDoR5RmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= M1vxTlI2PjZ5NUGw
MDA-MB-231 MnrWSpVv[3Srb36gRZN{[Xl? MniwNE01OCEEtV2= NYC1NIk4PC1{NDDo MWfpcoNz\WG|ZYOgR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NXrpcnNwOjV3OEezNlk>
MCF-7 NUH1S4duTnWwY4Tpc44hSXO|YYm= NXrNeIt4OC12MDFCuW0> NF7mR2w1NTJ2IHi= MXnlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh NIq0UlAzPTV6N{OyPS=>
MCF7-MX  MoP1SpVv[3Srb36gRZN{[Xl? NITkdVkxNTRyINM1US=> MV60MVI1KGh? MXHlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh NHX3emszPTV6N{OyPS=>
MDA-MB-231 NXHNfI9yTnWwY4Tpc44hSXO|YYm= M{D5[FAuPDBiwsXN MYS0MVI1KGh? NHrrcGp{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= MWGyOVU5PzN{OR?=
A2780 NYfJVo5sTnWwY4Tpc44hSXO|YYm= M33HUVUwOTBxMUWg{txO NGPHO4E1QCCq MWDk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NICyUY0zPTR{NEi5PC=>
SKOV3  MofkSpVv[3Srb36gRZN{[Xl? MnzVOU8yOC9zNTFOwG0> NYTscY44PDhiaB?= MmTw[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlnINlU1OjR6OUi=
A2780 NXe3bokyTnWwY4Tpc44hSXO|YYm= NVzoUHJrPS9zMD:xOUDPxE1? NFPhNok1QCCq M2rVPYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? MnjJNlU1OjR6OUi=
SKOV3  M{HSO2Z2dmO2aX;uJGF{e2G7 NUjDXYo{PS9zMD:xOUDPxE1? NUHXUXlOPDhiaB?= MnPl[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? M1fCblI2PDJ2OEm4
A2780 NFTuNmtHfW6ldHnvckBCe3OjeR?= NVjlSZVpPS9zMD:xOUDPxE1? M2jHSVQ5KGh? M{PodIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= NXvCeYpxOjV2MkS4PVg>
SKOV3  Ml7KSpVv[3Srb36gRZN{[Xl? MYS1M|ExNzF3IN88US=> M{P1b|Q5KGh? MoDY[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw MWeyOVQzPDh7OB?=
A2780 NXvDdFRkTnWwY4Tpc44hSXO|YYm= MkS5OU8yOC9zNTFOwG0> NHvRN|cyKGh? MnzYbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXeyOVQzPDh7OB?=
SKOV3  MVLGeY5kfGmxbjDBd5NigQ>? NUTHbpI1PS9zMD:xOUDPxE1? NFXBNHQyKGh? NF:zRpZqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWPBVY5TOjV2MkS4PVg>
HCT-15 NWq4NnNGTnWwY4Tpc44hSXO|YYm= NGLMUVIyOC13MDFOwG0> M{\HeFYuOzZiaB?= NILa[m5qdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MojhNlUzOThyMki=
HT-29  M2Xr[mZ2dmO2aX;uJGF{e2G7 MWexNE02OCEQvF2= NIO2V5E3NTN4IHi= NWj6XHpWcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NXHFVGV{OjV{MUiwNlg>
HSC3  NH[5WYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV6w5qCUPDBizszN Ml;oOFghcA>? NW\3PZB[UUN3ME2yOU42yrFzLke4NEDPxE1? M4PsbFI2OTl6N{i5
HSC3  MlO5RZBweHSxc3nzJGF{e2G7 NUDUSWl7OjVizszN Mn3vOFghcA>? Ml;abY5lfWOnczDhdI9xfG:|aYO= NX3JZXhiOjVzOUi3PFk>
HSC3  NUXvNYM4TnWwY4Tpc44hSXO|YYm= NVTDTWtGOjVizszN MkfWOFghcA>? M4fZPYV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? MYmyOVE6QDd6OR?=
HSC3  NYm0[Zc6TnWwY4Tpc44hSXO|YYm= NVG0[ZJ{OjVizszN Ml7xOFghcA>? MWTpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NG\BVVYzPTF7OEe4PS=>
HSC3  M{DjT2Z2dmO2aX;uJGF{e2G7 NWXhcZN[OjVizszN Mn;BO|IhcA>? MXfk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= NH3VZVUzPTF7OEe4PS=>
201T  NEDVcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nHOlczKGh? NGXz[pNFVVOR M1TiNmlEPTB;NEiuOkDDvU1? NGrkR4wzPTB3N{m0NS=>
273T M13tbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq3NkBp NFLiRnhFVVOR NXrDcodlUUN3ME24NE42KML3TR?= MkDnNlUxPTd7NEG=
Hep-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHaN|AwPTBxMUCwJO69VQ>? MYKxNk8zPC9|Nj:0PEBp MWTEUXNQ M1HFbIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{Oyc|I1QTl6NU[0
Hep-2 MWjBdI9xfG:|aYOgRZN{[Xl? NULWd|NRPTBizszN NUnuc29lOC12ODDo MnHiSG1UVw>? NYjZcGlmcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NXW1TW8zOjR7OUi1OlQ>
Hep-2 NXnqR3NWTnWwY4Tpc44hSXO|YYm= M3rsVVUxKM7:TR?= NHfrNoIxNTR6IHi= NEn6[JpFVVOR M3rONpJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 MnG0NlQ6QTh3NkS=
Hep-2 Ml:2SpVv[3Srb36gRZN{[Xl? Mk[5OVAh|ryP M4Lue|AuPDhiaB?= NUXyZZBDTE2VTx?= NGrFfJZl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? NImwXoczPDl7OEW2OC=>
SGC-7901 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXzbWxXOTBxNUCvNVAxKM7:TR?= MXiyOE81QC95MjDo MXfEUXNQ MmmybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWiyOFk6Ojl3OB?=
MKN-45 NESzdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNE82OC9zMECg{txO MlL0NlQwPDhxN{KgbC=> MnThSG1UVw>? NFLZbIdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NWDBOFRUOjR7OUK5OVg>
SGC-7901 M2nvd2Z2dmO2aX;uJGF{e2G7 M1L0O|ExNzVyL{GwNEDPxE1? MlnyOFghcA>? M4m5W2ROW09? MnXl[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVjKfpV{OjR7OUK5OVg>
MKN-45 MmT1SpVv[3Srb36gRZN{[Xl? M4fhd|ExNzVyL{GwNEDPxE1? MYm0PEBp NXr3SXJiTE2VTx?= MWHkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGLS[|gzPDl7Mkm1PC=>
C666-1 M2XRbWN6fG:2b4jpZ4l1gSCDc4PhfS=> NF\l[FYzOC16MDFOwG0> NEjxc3QzPCCq NYixSIZI\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NF;3N3EzPDh3NEizPC=>
CNE-1 NHfjbpJEgXSxdH;4bYNqfHliQYPzZZk> NGXyR5QzOC16MDFOwG0> M3fGdlI1KGh? M1Hwe4Rm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MoLVNlQ5PTR6M{i=
CNE-2 NEm4S4pEgXSxdH;4bYNqfHliQYPzZZk> MnHtNlAuQDBizszN M2\6XVI1KGh? MV3k[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NVrFZYI1OjR6NUS4N|g>
C666-1 NH7BOppEgXSxdH;4bYNqfHliQYPzZZk> NEfyWYM3OCEQvF2= NVXuOWUxPyCm NUL2Z5BJ\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NGrRWlczPDh3NEizPC=>
CNE-1 NH7nbmJEgXSxdH;4bYNqfHliQYPzZZk> NE\xR4Y3OCEQvF2= NEO4RW44KGR? MlLR[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= M1TzclI1QDV2OEO4
SNU-1041 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzrcJZyOC12MDFOwG0> NUnjVHFJPDhiaB?= NXXDUJdCcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M2XofFI1Pjl{N{Cz
SNU-1041 M1PwPGZ2dmO2aX;uJGF{e2G7 MVOyNE8{OCEQvF2= M4HyR|QhcA>? NIDEW2RqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? NGXlPZMzPDZ7MkewNy=>
SNU-1041 Mn\5SpVv[3Srb36gRZN{[Xl? NXXiWHdCOC12MDFOwG0> M4fxflQhcA>? MWr1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>? MV6yOFY6OjdyMx?=
SGC-7901 M3O0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWm1NE0yOjVizszN NWCxWGRbOjRxNEivO|IhcA>? MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2XlT|I1Pjd4M{m0
SGC-7901 NGD3dWpCeG:ydH;zbZMhSXO|YYm= MVuxNFAh|ryP MmTVO|IhcA>? MUfpcoR2[2W|IHHwc5B1d3Orcx?= MnjyNlQ3PzZ|OUS=
SGC-7901 NEe1eoJHfW6ldHnvckBCe3OjeR?= MoXHO|UwOTByL{GyOUDPxE1? NWO0S45COjRxNEivO|IhcA>? NXf6WWRMcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> NUTlRXllOjR4N{[zPVQ>
LMeC  NEPCNpVHfW6ldHnvckBCe3OjeR?= NF\3Z5kzOC93MDFOwG0> MnTMOFghcA>? NX;vXoRp\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEORWD2yJJBzd3SnaX6= M{HpXFI1PjV4N{S2
CMeC-1 NGPEcoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH22R3ozOC93MDFOwG0> M3vLOlQ5KGh? NVP3PXc3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NI\pSXAzPDZ3Nke0Oi=>
LMeC NXv1XHY1S2WubDDWbYFjcWyrdImgRZN{[Xl? MVeyNE82OCEQvF2= NXTjTY0yPDhiaB?= M4\TVIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Mn\qNlQ3PTZ5NE[=
CMeC-1 NXzZPZQ{TnWwY4Tpc44hSXO|YYm= NXjVNoRNOjBxNUCg{txO NEHTR5Y1QCCq NXvpV4ptcW6mdXPld{BIOS2VIHHydoV{fA>? NFPhTIwzPDZ3Nke0Oi=>
LMeC NFu0eHpHfW6ldHnvckBCe3OjeR?= MkLUNlAwPTBizszN MUK0PEBp Ml7NbY5lfWOnczDHNU1UKGG{cnXzeC=> MWWyOFY2Pjd2Nh?=
CMeC-1 NY\PbotNTnWwY4Tpc44hSXO|YYm= NYfyPJVTOjBxNUCg{txO M2HoelQ5KGh? Mne4[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUTkOXNOOjR4NU[3OFY>
LMeC MYrGeY5kfGmxbjDBd5NigQ>? Mnf5NlAwPTBizszN NGe0NlI1QCCq NUfHTIky\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWnmWnR5OjR4NU[3OFY>
CMeC-1 MnTmSpVv[3Srb36gRZN{[Xl? MX:yNE82OCEQvF2= MX[0PEBp NI\hR3VqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MnzzNlQ3PTZ5NE[=
LMeC MUTGeY5kfGmxbjDBd5NigQ>? NGPnV5YzOC93MDFOwG0> MmL4OFghcA>? NYCyWoZ7cW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? NFOxNYozPDZ3Nke0Oi=>
OVCAR-3 MlnzR4VtdCCYaXHibYxqfHliQYPzZZk> MV6xNEDDvU1? NHqxbG8yKGh? NF3BUWFmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh Mn3zNlQ2OjB{Mke=
OVCAR-3 M4PNPGFxd3C2b4Ppd{BCe3OjeR?= NWW3Zo8zOTBiwsXN NXPsWVFYOSCq MnfCdJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh NFvYVGwzPDV{MEKyOy=>
OVCAR-3 NXnJ[IR7TnWwY4Tpc44hSXO|YYm= NGTsSFYyOCEEtV2= NHPrWFYyKGh? NFzIeVdmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=> MlXSNlQ2OjB{Mke=
OVCAR-3 NF3hO|hHfW6ldHnvckBCe3OjeR?= MmX2NVAhyrWP M1;QN|EhcA>? M{H6R4Rwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> NWrUSYFZOjR3MkCyNlc>
OVCAR-3 NYLJd|VtTnWwY4Tpc44hSXO|YYm= M4H3flExKML3TR?= MUWxJIg> NIXy[ndqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NIDVd5czPDV{MEKyOy=>
CF33 NVnCfFhDTnWwY4Tpc44hSXO|YYm= NWr2cHNvOTByIN88US=> NHjEZWgzPCCq NHXsZnhqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= MUSyOFUxOzd6Mh?=
CF33 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DhVVExNTFyMDFOwG0> NXPyNIJHOC12IHS= MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVvsfVlHOjR3MEO3PFI>
CF33 MYTGeY5kfGmxbjDBd5NigQ>? M3u1ZlExNTFyMDFOwG0> MUG0MVI1KGh? M4e2e4Rm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? MVGyOFUxOzd6Mh?=
LNCaP NFLLbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLwWlZuOi93L{GwJO69VQ>? MmHZPVYhcA>? NVPjeWVScW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NXHnSI9sOjR{OU[5O|g>
LNCaP MlO5RZBweHSxc3nzJGF{e2G7 MlPMNk82NzFyIN88US=> MYO5OkBp NUDkUXFjcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> MXmyOFI6Pjl5OB?=
PC-3  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LP[VAuPTBizszN NYLwW|FIPDkkgJno NFPyWlRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MkHxNlQyOjd6OEK=
PC-3  MmS0R4VtdCCYaXHibYxqfHliQYPzZZk> NVrkdVEyOC1zMECg{txO M3jHbVczKGh? NVzGblFK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M2fONVI1OTJ5OEiy

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03896113 Not yet recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain June 30 2019 Phase 2
NCT03643744 Recruiting Drug: Celecoxib 200mg|Drug: Placebo Actinic Keratosis|Photodynamic Therapy Jeffrey B. Travers MD PhD|Wright State Physicians April 1 2019 Phase 1
NCT01344200 Not yet recruiting Drug: Celecoxib Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT02876094 Recruiting Drug: celecoxib Spinal Muscular Atrophy (SMA) Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children''s Hospital of Eastern Ontario January 29 2019 Phase 2
NCT03672162 Recruiting Procedure: Total abdominal hysterectomy Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib Rajavithi Hospital September 1 2018 Not Applicable
NCT03541655 Active not recruiting Drug: Bupivacaine HCl|Drug: F14 (celecoxib) Total Knee Replacement|Postoperative Pain Arthritis Innovation Corporation May 4 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID